Related references
Note: Only part of the references are listed.Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy
Sotirios Tsiodras et al.
MAYO CLINIC PROCEEDINGS (2012)
The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome
Houli Wang et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2008)
TNF alpha blockade in human diseases: An overview of efficacy and safety
Jan Lin et al.
CLINICAL IMMUNOLOGY (2008)
Malignancy and biologic therapy in rheumatoid arthritis
Johan Askling et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Monoclonal antibody first dose cytokine wease syndromes-mechanisms and prediction
Mark Wing
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Protein therapeutics: A summary and pharmacological classification
Benjamin Leader et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
Christine H. Chung
ONCOLOGIST (2008)
Drug-induced lupus due to anti-tumor necrosis factor α agents
Michelle F. Costa et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)
Epoetin-induced pure red cell aplasia: diagnosis and treatment
Lain C. Macdougall
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2007)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
Aya Jakobovits et al.
NATURE BIOTECHNOLOGY (2007)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Loreto Carmona et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Infectious complications of monoclonal antibodies used in cancer therapy - A systematic review of the evidence from randomized controlled trials
Petros I. Rafailidis et al.
CANCER (2007)
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy:: A review of 84 cases
Nirmal Kaur et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics
Shalini Gupta et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
D. S. Goodin et al.
NEUROLOGY (2007)
Opinion - Preclinical safety testing of monoclonal antibodies: the significance of species relevance
Kathryn Chapman et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Bacterial and opportunistic infections during anti-TNF therapy
Anja Strangfeld et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Natalizumab and progressive multifocal leucoencephalopathy
J. R. Berger
ANNALS OF THE RHEUMATIC DISEASES (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Methods of evaluating immunotoxicity
Jacques Descotes
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Effects of protein aggregates: An immunologic perspective
Amy S. Rosenberg
AAPS JOURNAL (2006)
Side effects of interferon-α therapy
S Sleijfer et al.
PHARMACY WORLD & SCIENCE (2005)
Tolerability and safety of rituximab (MabThera®)
E Kimby
CANCER TREATMENT REVIEWS (2005)
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Systemic allergy to human insulin and its rapid and long acting analogs:: successful treatment by continuous subcutaneous insulin lispro infusion
V Castéra et al.
DIABETES & METABOLISM (2005)
Infections associated with tumor necrosis factor-alpha antagonists
DJ Rychly et al.
PHARMACOTHERAPY (2005)
Thyroid autoimmunity and dysfunction associated with type I interferon therapy
F Monzani et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2004)
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
J Clarke et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2004)
Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case
A Stallmach et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Structure-immunogenicity relationships of therapeutic proteins
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2004)
Preclinical safety testing of biotechnology-derived pharmaceuticals - Understanding the issues and addressing the challenges
FR Brennan et al.
MOLECULAR BIOTECHNOLOGY (2004)
Reactivation of latent tuberculosis infection in TNF-deficient mice
T Botha et al.
JOURNAL OF IMMUNOLOGY (2003)
Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab
V Baudouin et al.
TRANSPLANTATION (2003)
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents
NR Slifman et al.
ARTHRITIS AND RHEUMATISM (2003)
Outlook - Preclinical safety evaluation of biotechnology-derived pharmaceuticals
JA Cavagnaro
NATURE REVIEWS DRUG DISCOVERY (2002)
Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion
DL Riegert-Johnson et al.
INFLAMMATORY BOWEL DISEASES (2002)
Potential anaphylactic shock with abciximab readministration
C Pharand et al.
PHARMACOTHERAPY (2002)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology
VP Mohan et al.
INFECTION AND IMMUNITY (2001)
Share Paper
